Bob G. S. Abeln

Bob G. S. Abeln

Auto-generated profile, based on publicly available information

Bob G. S. Abeln

Department of Cardiology St. Antonius Hospital Nieuwegein The Netherlands

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2021 in European Heart Journal
Verified
Journal Article
Open access
PDF file
TVTom E Verstraelen
Tom E Verstraelen
FLFreyja H M van Lint
Freyja H M van Lint
LBLaurens P Bosman
Laurens P Bosman
RBRemco de Brouwer
Remco de Brouwer
VPVirginnio M Proost
Virginnio M Proost
AWArthur A M Wilde
Arthur A M Wilde
This study aims to improve risk stratification for primary prevention implantable cardioverter defibrillator (ICD) implantation by developing a new mutation-specific prediction model for malignant ventricular arrhythmia (VA) in phospholamban (PLN) p.Arg14del mutation carriers. The proposed model is compared to an existing PLN risk model. Data were collected from PLN p.Arg14del mutation carriers with no history of malignant VA at baseline, identified between 2009 and 2020. Malignant VA was defined as sustained VA, appropriate ICD intervention, or (aborted) sudden cardiac death. A prediction model was developed using Cox regression. The study cohort consisted of 679 PLN p.Arg14del mutation carriers, with a minority of index patients (17%) and male sex (43%), and a median age of 42 years [interquartile range (IQR) 27–55]. During a median follow-up of 4.3 years (IQR 1.7–7.4), 72 (10.6%) carriers experienced malignant VA. Significant predictors were left ventricular ejection fraction, premature ventricular contraction count/24 h, amount of negative T waves, and presence of low-voltage electrocardiogram. The multivariable model had an excellent discriminative ability {C-statistic 0.83 [95% confidence interval (CI) 0.78–0.88]}. Applying the existing PLN risk model to the complete cohort yielded a C-statistic of 0.68 (95% CI 0.61–0.75). This new mutation-specific prediction model for individual VA risk in PLN p.Arg14del mutation carriers is superior to the existing PLN risk model, suggesting that risk prediction using mutation-specific phenotypic features can improve accuracy compared to a more generic approach. Malignant VA risk prediction in PLN p.Arg14del carriers. With the mutation specific risk factors low and high risk groups can be identified. PLN, Phospholamban; VA, Ventricular arrhythmia.

12 June 2025 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Open access
BABob G. S. Abeln
Bob G. S. Abeln
MGMarisa van der Graaf
Marisa van der Graaf
DMDan L. Musat
Dan L. Musat
MGMelanie A. Gunawardene
Melanie A. Gunawardene
DNDevi G. Nair
Devi G. Nair
LBLucas V. A. Boersma
Lucas V. A. Boersma
Background: There are few comparative studies on the everyday clinical outcomes of commercially available pulsed field ablation (PFA) systems for atrial fibrillation (AF). Objective: This study evaluates the acute efficacy and safety outcomes of the FARAPULSE™ (pentaspline catheter) and PulseSelect™ (circular catheter) system. Methods: International, multicenter, registry on patients with paroxysmal or persistent AF, undergoing a first ablation using either PFA system between January 29th, 2024 and September 1st, 2024. Primary endpoints were electrical isolation of ablation targets, procedural characteristics and freedom from major adverse events within 30 days postprocedure. Results: A total of 402 patients were enrolled at the six participating centers, of whom 56.5% were treated with the pentaspline ablation‐catheter. Acute procedural efficacy was 100% for both groups. Use of the pentaspline ablation‐catheter was associated with significantly shorter procedural times (36.0 min [IQR 31.0; 44.0] vs. 49.0 min [IQR 41.5;76.0]) compared to the circular ablation‐catheter ( p < 0.001). Major adverse events were scarce and not different between cohorts. Two patients (0.5%) experienced a stroke and one patient (0.2%) had a serious vascular access site complication. One patient had a transient ischemic attack (0.2%). Minor vascular access site complications were more common in the pentaspline catheter group (11.9% vs. 1.1%, p < 0.001). Conclusions: This study showed excellent acute efficacy and safety for both PFA‐systems. Our findings reveal shorter procedural times with the pentaspline catheter, less minor access site complications with the circular catheter, and several procedural differences between the ablation systems, often driven by operator choice.

25 February 2021 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
BABob G.S. Abeln
Bob G.S. Abeln
JBJohannes L.P.M. van Den Broek
Johannes L.P.M. van Den Broek
VDVincent F. van Dijk
Vincent F. van Dijk
JBJippe C. Balt
Jippe C. Balt
MWMaurits C.E.F. Wijffels
Maurits C.E.F. Wijffels
LBLucas V.A. Boersma
Lucas V.A. Boersma

12 September 2025 in EP Europace
Verified
Journal Article
Open access
MGM van der Graaf
M van der Graaf
JAJason G Andrade
Jason G Andrade
SKS Kibel
S Kibel
MBM Bennett
M Bennett
RBR Bennett
R Bennett
LBL V A Boersma
L V A Boersma

1 November 2024 in Journal of Arrhythmia
Verified
Journal Article
Open access
JBJippe Balt
Jippe Balt
BAB. G. S. Abeln
B. G. S. Abeln
VDV. F. van Dijk
V. F. van Dijk
MWM. C. E. F. Wijffels
M. C. E. F. Wijffels
MLM. Liebregts
M. Liebregts
LBL. V. A. Boersma
L. V. A. Boersma
Introduction: High‐density (HD) substrate mapping may increase success of catheter ablation targeting ventricular tachycardia (VT). However, despite its use, recurrent VT is not uncommon. We aim to investigate factors that are associated with outcomes after HD mapping‐guided substrate ablation procedures for VT in patients with ischemic cardiomyopathy.Methods: Observational cohort study includes patients with ischemic heart disease who underwent HD mapping‐guided substrate ablation of VT. Baseline and procedural characteristics were associated with outcomes after VT ablation.Results: VT ablation employing HD mapping was performed in 80 patients. Median follow‐up was 2.3 years. VT‐free survival at one, two, and five years were 65%, 49%, and 40%. One‐, two‐, and five‐year implantable cardioverter defibrillator (ICD) shock‐free survival rates were 90%, 81%, and 70%. Complications occurred in 3 patients (3.8%, 1 vascular, 2 tamponades). Left ventricular ejection fraction (LVEF) and 45 W (vs. 35 W) ablation power were associated with VT‐free survival. High ablation power was also associated with shock‐free survival. All‐cause mortality during follow‐up was associated with higher age, the presence of chronic obstructive pulmonary disease (COPD), LVEF, and urgent ablation.Conclusions: In patients with ischemic cardiomyopathy that had HD substrate mapping‐guided VT ablation, ablation power was associated with both VT‐free and shock‐free survival, underlining the importance of effective target elimination. All‐cause mortality during follow‐up was associated with several factors (age, COPD, LVEF, and urgent vs. elective ablation), which could be used to guide patient selection for VT ablation.

27 March 2025 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Open access
BABob G. S. Abeln
Bob G. S. Abeln
LALucio Addeo
Lucio Addeo
TPTom De Potter
Tom De Potter
LBLucas V. A. Boersma
Lucas V. A. Boersma
Background: Ultra‐low temperature cryoablation (ULTC) is a technique designed to rapidly cool cardiac tissue to extremely low temperatures, enabling the creation of ablation lesions for the treatment of atrial fibrillation (AF). Prior studies have demonstrated low rates of arrhythmia recurrence, but little is known about ablation lesion durability.Methods: Patients undergoing repeat ablation were selected from the CryoCure2 (NCT02839304) and iCLAS PMCF(NCT05416086) studies. Baseline patient and ULTC procedure characteristics were evaluated. During repeat ablation, ULTC ablation lesions were assessed for electrical block, including segment‐based assessment of pulmonary vein (PV) ablation lesions. Arrhythmia outcomes after repeat ablation were evaluated.Results: Twenty‐five patients were included in the cohort: Age 68 ± 7 years, male 68%, persistent AF 68%, LAVI 42 ± 24 mL/m2. During index procedure, ULTC was used to target the PVs in all patients, the left atrium posterior wall (LAPW) in 15 patients, the lateral mitral isthmus (LMI) in five patients and the cavotricuspid isthmus (CTI) in two patients. At repeat ablation, PV reconnection was observed in 21/25 patients (55/100 PVs reconnected), and reconnection occurred most often in the anterior segments of the left PVs. The LAPW lesion was incomplete in 4/15 patients, the LMI in 3/5 and the CTI in 1/2. After repeat ablation, 10/25 patients had arrhythmia recurrence.Conclusion: Reconnection of ablation targets during repeat ablation for arrhythmia recurrence following ULTC occurred at rates comparable to those observed with conventional thermal ablation modalities. The anterior side of the left PVs appears to be reconnected most often.